{"id":59301,"date":"2026-06-09T14:31:12","date_gmt":"2026-06-09T14:31:12","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/59301\/"},"modified":"2026-06-09T14:31:12","modified_gmt":"2026-06-09T14:31:12","slug":"pharmalittle-gsk-agrees-to-buy-nuvalent-cancer-drug-developer","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/59301\/","title":{"rendered":"Pharmalittle: GSK agrees to buy Nuvalent cancer drug developer"},"content":{"rendered":"

Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. Who could ask for anything more? Actually, we could \u2014\u00a0it is time to reheat the kettle for another cuppa stimulation. Our choice today is raspberry hibiscus. And here is a helpful tip: A teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are hawking replicas \u2014\u00a0take a look<\/a>. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. \u2026<\/p>\n

GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology, STAT<\/a> writes. The deal is the latest in a run of biopharma acquisitions in recent months, as large and even midsize companies have been looking to bolster their pipelines as some of their key products face looming generic competition. This latest deal is one of the largest in the recent buying spree, and GSK\u2019s largest in years. Nuvalent designs targeted cancer therapies, with two molecules both under U.S. Food and Drug Administration review for types of non-small cell lung cancer. They could be approved this year.\u00a0 The deal will give GSK, which has focused on gynecologic cancers as well as multiple myeloma, a broader lung cancer portfolio.\u00a0<\/p>\n

Merck and Gilead Sciences disclosed that an experimental long-acting pill combining two HIV medicines had met its primary efficacy goal in final-stage trials, Bloomberg News<\/a> notes. The companies said that in two large trials, a once-weekly combination pill containing Merck\u2019s islatravir and Gilead\u2019s lenacapavir had proven to be \u201cnon-inferior\u201d to standard pill regimens that are taken daily. If approved by regulators, the new combination could become the first once-weekly pill for the treatment of HIV. \u00a0A once-weekly pill would provide a less-frequent dosing option that does not require an injection. Gilead currently sells a different version of lenacapavir as a twice-yearly injectable to prevent the disease under the brand name Yeztugo.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Rise and shine, everyone, another busy day is on the way. And it is getting off to a…\n","protected":false},"author":2,"featured_media":50049,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,25092,20102],"class_list":["post-59301","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-pharmalittle","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116720637304221787","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/59301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=59301"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/59301\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/50049"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=59301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=59301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=59301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}